Academia.eduAcademia.edu

Outline

Title
Abstract
Preliminary Studies Case Study
Introduction
Methodology
Statistical Analysis
Results
Demographic Data
Discussion
Conclusion
References

Secondary Surfactant Dysfunction and Deficiency

Profile image of Robin BissingerRobin Bissinger

2007

Abstract

Based on literature in Adult Respiratory Distress Syndrome in humans and evidence of surfactant activation in vitro and vivo, and our clinical observations of secondary respiratory decompensation in premature infancies recovering from RDS, a study was designed to look at the possibility of benefit from secondary surfactant administration in premature infancies with secondary decompensation after recovery from respiratory distress syndrome (RDS). A prospective pilot study was performed to study the effects of secondary surfactant administration on oxygenation, ventilation and pulmonary function of neonates who had respiratory decompensation after recovery from RDS. A secondary data analysis was performed looking at pulmonary function related to ventilatory efficiency index (VEI), modified ventilatory index (MVI) and respiratory severity score (RSS). Entry criteria included infants admitted with RDS who were 7 days to 3 months of age, with birth weights ≥ 500 grams. Infants qualified ...

Related papers

Double-blind 1-year follow-up of 1540 infants with respiratory distress syndrome randomized to rescue treatment with two doses of synthetic surfactant or air in four clinical trials. American and Canadian Exosurf Neonatal Study Groups
Donnal Walter

The Journal of Pediatrics, 1995

Synthetic surfactant has been shown to reduce neonatal and l-year mortality and neonatal morbidity in infants with respiratory distress syndrome. However, less is known about the effects of synthetic surfactant on developmental outcome and long-term morbidity. Four multicenter, randomized, placebocontrolled trials of synthetic surfactant administered as rescue therapy were conducted in the United States and Canada, with a total enrollment of 2224 patients. Double-blind developmental evaluations of survivors were conducted at I year of age (adjusted for prematurity) in all four trials. Of the 1802 patients enrolled in the placebo-controlled rescue trials who survived to I year, 1540 (85%) completed the l-year follow-up evaluation. Height, weight, and head circumference measurements were not different in the treatment and control groups. Mean and median Bayley Scores of Infant Development for both the Mental Development Index and the Psychomotor Development Index were also equivalent. The incidence of impairments was not different in the two groups (mild to moderate impairment, 12% [92 of 745] for the air placebo group vs 11% [86 of 771] for the synthetic surfactant group; severe impairment, 15% [114 of 745] for the air placebo group vs 13% [102 of 771] for the synthetic surfactant group). No differences in rates of retinopathy of prematurity or hearing impairment were found in the treatment groups. The need for surgery after day 28 of life (relative risk, 0.779; 95% confidence interval, 0.665, 0.927) and the need for respiratory support at I year (relative risk, 0.525; 95% confidence intervals, 0.303, 0.941) were both reduced in the synthetic surfactant group. These results indicate that developmental outcome at 1 year of age is at least as good among infants with respiratory distress syndrome who received rescue therapy with synthetic surfactant as it is in infants who received air placebo; the results also indicate that the incidence of long-term morbidity is reduced.

View PDFchevron_right
Surfactant Administration by Transient Intubation in Infants 29 to 35 Weeks' Gestation with Respiratory Distress Syndrome Decreases the Likelihood of Later Mechanical Ventilation: A Randomized Controlled Trial
Rita Ryan

Journal of Perinatology, 2005

To assess, among premature infants with early respiratory distress syndrome (RDS), the effect of one dose of intratracheally administered surfactant followed by extubation to nasal continuous positive airway pressure (NCPAP) on subsequent mechanical ventilation (MV), when compared with NCPAP alone.

View PDFchevron_right
Is there a Difference in Surfactant Treatment of Respiratory Distress Syndrome in Premature Neonates? A Review
Karen Kamholz

Journal of Pulmonary and Respiratory Medicine, 2013

Exogenous surfactant treatment of premature infants with Respiratory Distress Syndrome (RDS) has been the standard of care for more than two decades. There are now many studies comparing various surfactant preparations. Data are clear that the synthetic surfactants without surfactant proteins are inferior to animal derived surfactant preparations. In the United States, commercially available surfactants are beractant, calfactant, poractant alfa, and lucinactant. Relative efficacy of the various available animal derived surfactants in the United States appear to favor poractant alfa, the surfactant preparation with the highest concentrations of phospholipids and high concentration of surfactant proteins, allowing a higher initial dose of phospholipids in preterm infants less than 32 weeks. A new synthetic surfactant with a surfactant protein analog, lucinactant, has been recently been approved for use in the United States. Synthetic surfactants hold the possibility of surfactant treatments without potential animal-born infectious agents or animal proteins that could induce an immune response in fragile premature infants with multiple medical problems. New surfactant administration strategies are described, complimenting new respiratory support strategies, designed to minimize invasive mechanical ventilation and decrease the frequency of chronic lung disease. Minimally invasive surfactant administration strategies are being developed to accommodate these new respiratory support strategies. The goal of this manuscript is to review the available surfactant preparations and their administration strategies.

View PDFchevron_right
Early administration of the second surfactant dose in preterm infants with severe respiratory distress syndrome
Nilgün Koksal

The Turkish journal of pediatrics

The aim of this study was to determine whether early administration (2 hours after the first surfactant dose) of the second surfactant dose would be superior to late surfactant treatment (6 hours after the first surfactant dose) in preterm infants with severe respiratory distress syndrome. Between June 2003 and March 2005, 40 newborns born with respiratory distress syndrome in Uludağ University Hospital were investigated in this prospective study. The inclusion criteria for the recruitment of the infants were: age < or = 2 hours, birth weight between 600-2500 g, gestational age between 24-36 weeks, X-ray consistent with respiratory distress syndrome, and need for mechanical ventilation with inspiratory oxygen fraction > or = 0.4 and mean airway pressure > or = 7 cm H2O to obtain arterial pressure of oxygen between 70-80 mmHg. Infants with lethal congenital anomalies or being treated with high-frequency oscillatory ventilation were excluded from the study. Birth weight, gest...

View PDFchevron_right
One-year follow-up evaluation of 260 premature infants with respiratory distress syndrome and birth weights of 700 to 1350 grams randomized to two rescue doses of synthetic surfactant or air placebo
David Burchfield

The Journal of Pediatrics, 1995

A multicenter, randomized, double-blind, placebo-controlled trial of synthetic surfactant therapy for premature infants with respiratory distress syndrome (RDS) and birth weights of 700 to 1350 gm demonstrated a reduction in severity of RDS, morbidity, and neonatal and l-year mortality. Of the 419 infants who were entered in the study, 80% of the surviving infants in both the air placebo group (122) and the synthetic surfactant group (138) returned for the follow-up evaluation at l-year adjusted age. The only significant difference observed at follow-up was a reduction in the incidence of mild cerebral palsy in the synthetic surfactant group (air placebo group, 8 of 122 [7%]; synthetic surfactant group, 3 of 138 [2%]; relative risk 0.306; 95% confidence interval 0.094, 0.999). No differences were observed between the air placebo and synthetic surfactant treatment groups with respect to health status of the infants, including the incidence of retinopathy of prematurity and neurodevelopmental delays. The difference in the overall incidence of impairment among the l-year survivors in the air placebo group (43 of '122 [35%]) and in the synthetic surfactant group (40 of 138 [29%]) was not statistically significant. The results of this l-year follow-up study show that rescue treatment with synthetic surfactant in infants weighing 700 to 1300 gm is not associated with adverse developmental consequences despite the improvement in survival.

View PDFchevron_right
Surfactant therapy in preterm infants with respiratory distress syndrome and in near-term or term newborns with acute RDS
Rangasamy Ramanathan

Journal of Perinatology, 2006

Many different surfactant preparations derived from animal sources, as well as synthetic surfactants, are available for the treatment of preterm infants with respiratory distress syndrome (RDS). Natural, modified surfactants containing surfactant-associated proteins appear to be more effective than non-protein-containing synthetic surfactants. Comparative trials with poractant alfa at a higher initial dose of 200 mg/kg appear to be associated with rapid weaning of FiO 2 , less need for additional doses, and decreased mortality in infants <32 weeks gestation when compared with beractant. Early rescue (<30 min of age) surfactant therapy is an effective method to minimize over treatment of some preterm infants who may not develop RDS. Surfactant therapy followed by rapid extubation to nasal ventilation appears to be more beneficial than continued mechanical ventilation. In near-term or term newborns with acute RDS, surfactant therapy has been shown to be 70% effective in improving respiratory failure.

View PDFchevron_right
The choice of surfactant for treatment of respiratory distress syndrome in preterm infants: A review of the evidence There are many clinical trials of surfactant therapy in newborn babies, but making valid comparisons between surfactant preparations is problematic due to the different doses, volu...
Uma Sothinathan

2005

View PDFchevron_right
Double-blind, randomized, placebo-controlled Canadian multicenter trial of two doses of synthetic surfactant or air placebo in 224 infants weighing 500 to 749 grams with respiratory distress syndrome
Koravangattu Sankaran

The Journal of Pediatrics, 1995

In a multicenter, double-masked, placebo-controlled rescue trial conducted at 12 Canadian hospitals, two 5 ml/kg doses of a synthetic surfactant or air placebo were administered to 224 infants with birth weights of 500 to 749 gm who had established respiratory distress syndrome and an arterial/alveolar oxygen tension ratio of less than 0.22. The first dose was given between 2 and 24 hours of age; the second dose was given 12 hours later to the infants continuing to receive mechanical ventilation. Infants were stratified at study entry by birth weight and gender. Infants receiving synthetic surfactant showed significant improvements in alveolar-arterial oxygen tension gradient, arterial/alveolar oxygen tension ratio, and oxygen and ventilator requirements through day 7. In the group randomized to synthetic surfactant, significant improvements were seen in oxygen requirements at the first time point measured (2 hours; p = 0.02), in the alveolar-arterial oxygen tension gradient by the second time point measured (6 hours; p = 0.03), and in mean airway pressure after 6 hours. Overall mortality at 28 days was not significantly different in the two groups (50% vs 46%, air placebo group vs synthetic surfactant group; p = 0.586). Similarly, neither the incidence of bronchopulmonary dysplasia (37% vs 30%, air placebo group vs synthetic surfactant group; p = 0.089) nor the incidence of survival without BPD through 28 days (17% vs 26%, respectively; p = 0.070) was significantly different in the two groups. No significant differences in the incidence of safety-related outcomes or in adverse effects such as apnea or pulmonary hemorrhage were noted. These findings indicate that rescue therapy with synthetic surfactant results in physiologic improvements in very tiny premature infants, but improvements in overall mortality or other complications of respiratory distress syndrome were not documented in the sample evaluated.

View PDFchevron_right
Early versus delayed surfactant administration in extremely premature neonates with respiratory distress syndrome ventilated by high-frequency oscillatory ventilation
Václav Sebroň

Intensive Care Medicine, 2002

Objective: To determine whether early surfactant administration is superior to selective delayed treatment in terms of improving survival and/or reducing chronic lung disease in extremely premature neonates with respiratory distress syndrome (RDS) treated by high-frequency oscillatory ventilation (HFOV). Design: Prospective randomized clinical trial. Setting: Tertiary neonatal intensive care unit (NICU) in the Perinatology Center of Prague. Patients: Forty-three extremely premature infants who needed artificial ventilation within 3 h after delivery. Interventions: Patients were randomly assigned to either early (n=21) or delayed (n=22) administration of surfactant. All were ventilated by HFOV as the primary mode of ventilation using the high volume strategy aimed at optimizing lung volume. Curosurf at a dose of 100 mg/kg was given as a single bolus via the endotracheal tube within 1 min immediately after intubation in the early group (EARL), or during HFOV only when defined criteria were reached in the delayed (DEL) group. Measurements and results: No differences were noted in demographic data between the two groups. Fewer infants randomized to the EARL group required oxygen use or died at 36 weeks (combined outcome 29% vs 64%, p=0.021), and there was a lower incidence of any intraventricular hemorrhage in this group (43 vs 82%, p=0.008). Conclusions: When compared to delayed dosing, early administration of surfactant followed by HFOV facilitates and accelerates respiratory stabilization during the acute phase of severe RDS, may reduce the incidence of chronic lung disease or death and may positively influence the incidence of severe intracranial pathology in extremely premature infants with primary surfactant insufficiency.

View PDFchevron_right
Pulmonary mechanics in ventilated preterm infants with respiratory distress syndrome after exogenous surfactant administration: A comparison between two surfactant preparations
Michael Fayon

Pediatric Pulmonology, 1994

The effects of two surfactant preparations on lung mechanics have been studied on 24 ventilated premature infants with respiratory distress syndrome (RDS): 13 were given artificial surfactant (Exosurf Neonatal, Burroughs-Wellcome) and 1 1 natural porcine surfactant (Curosurf, Laboratoire Serono France). Measurements of respiratory system compliance ( C, , , , CJ and resistance ( R, ) were performed immediately before surfactant administration and repeated 6, 18, 24, 48, and 72 hours later. With Exosurf treatment, 6 hours after surfactant administration inhaled 0 , concentration (FI0 ) could be lowered from (0.72 5 0.20, to 0.62 5 0.33; P < 0.05), whereas C, , did not change f0.37 mUcmH,O/kg, % 0.14 vs. 0.39 f 0.12, NS). After 24 hours and during the following days a significant increase in C , occurred (24 hours post-Exosurf: 0.51 +-0.18, P < 0.05). With Curosurf treatment, the improvement in oxygenation was greater and F , , could be lowered much more after 6 hours (from F,02, 0.78 2 0.23 to 0.34 2 0.11, P < 0.01). This was associated with an increase in C , (from 0.39 * 0.09 to 0.59 T 0.17, P < 0.05). During the following days, C , was significantly higher in the group treated with

View PDFchevron_right

References (251)

  1. Kattwinkel, J: Surfactant: Evolving Issues. Clinics in Perinatology 1998; 25(1): 17-32.
  2. Avery, ME, Mead, J: Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 1959; 97:517-523.
  3. Jobe, AH, Ikegami, M: Biology of surfactant. Clinics in Perinatology 2001; 28(3): 655-669.
  4. Lewis, JF, Jobe, AH: Surfactant and the adult respiratory distress syndrome. Am Rev Respir Dis 1993; 147:218-233.
  5. Sunshine, P: The Experts Discuss Emerging Issues in Surfactant Replacement Therapy. Proceedingfrom Round Table Discussion 1991; B. W. Co: 1-51.
  6. Poynter, S, LeVine, A: Surfactant biology and clinical application. Critical Care Clinics 2003; 19:459-472.
  7. Morton, NS: Exogenous surfactant treatment for the adult respiratory distress syndrome? A historical perspective. Thorax 1990; 45:825-830.
  8. Crouch, E, Wright, J: Surfactant proteins A and D and pulmonary host defense. Annu Rev Physiol2001; 63:521-524.
  9. Suresh, GK, SolI. RF: Current surfactant use in premature infants. Clinics in Perin a to logy 2001; 28(3):671-694.
  10. Ainsworth, S, Milligan, DW A: Surfactant therapy for respiratory distress syndrome in premature neonates. Am J Respir Med 2002; 1(6):417-433.
  11. Merritt, TA., Hallman, M, Spragg, R, et al: Exogenous surfactant treatments for neonatal respiratory distress syndrome and their potential role in the adult respiratory distress syndrome. Drugs 1989: 38(4):591-611.
  12. Coalson, JJ, King, RI, Yang, F, et al: SP-A deficiency in primate model of bronchopulmonary dysplasia with infection. Am J_Respir Crit Care Med 1995; 151: 854- 866.
  13. Taeusch, HW: Treatment of acute (adult) respiratory distress syndrome. The Holy Grail of surfactant therapy. Biology of the Neonate 2000; 77(suppl 1 ):2-8.
  14. Goerke, J, Clements, J: Alveolar surface tension and lung surfactant, in Handbook of Physiology. Bethesda, MD, 1986, pp 247-261.
  15. Wiswell, TE: Expanded uses of surfactant therapy. Clinics in Perinatology 2001; 28(3):695-711.
  16. Bose, C, Corbet, A, Bose, G, et al: Improved outcome at 28 days of age for very low birth weight infants treated with a single dose of a synthetic surfactant. Journal of Pediatrics 1991; 117(6): 947-953.
  17. Corbet, A, Bucciarelli, R, Goldman, S, et al: Decreased mortality rate among small premature infants treated at birth with a single dose of synthetic surfactant: a multicenter controlled trial. American Exosurf Pediatric Study Group 1. Journal of Pediatrics 1991; 118(2):277-284.
  18. Corbet, A, Long, WA, Murphy, DJ, et al: Reduced mortality in small premature infants treated at birth with a single dose of synthetic surfactant. Journal of Paediatrics & Child Health 1991; 27(4):245-249.
  19. Long, W, Corbet, A, Cotton, R, et al: A controlled trial of synthetic surfactant in infants weighing 1250g or more with respiratory distress syndrome The American ExosurfNeonatal Study Group 1 and the Canadian ExosurfNeonatal Study Group. New England Journal of Medicine 1991; 325(24):1696-1703.
  20. Horbar, J, Wright, LL, SolI, RF, et al: A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network. Journal of Pediatrics 1993; 123(5):757-766.
  21. Hudak, M, Farrell, EE, Rosenberg, AA, et al: A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. Journal of Pediatrics, 1996; 128(3):396-406.
  22. Vermont Oxford Network: A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant in the treatment of neonatal respiratory distress syndrome. Pediatrics 1996; 97(1):1-6.
  23. Creuwels, LAJM, van Golde, LMG, Haagsman, HP: The pulmonary surfactant system: Biochemical and clinical aspects. Lung 1997; 175: 1-39.
  24. Enhoming, G, Shennan, A, Possmayer, F, et al: Prevention of neonatal respiratory distress syndrome by tracheal administration of surfactant: A randomized clinical trial. Pediatrics 1985; 76:145-153.
  25. Dekowski, SA, Holtzman, RB: Surfactant replacement therapy. Pediatric clinics of North America 1998; 45(3):549-572.
  26. Khammash, H, Perlman, M, Wojtulewics, J, et al: Surfactant therapy in full-term neonates with severe respiratory failure. Pediatrics 1993; 92(1):135-139.
  27. Shapiro, D, Notter, R, Morin, F, et al: Double blind, randomized trial ofa calf lung surfactant extract, administered at birth to very premature infants for prevention of respiratory distress syndrome. Pediatrics 1986; 76:593-595.
  28. Vallis-i-Soler, A, Femandez-Ruanova, B, Lopez-Heredia y Goya, J, et al: A randomized comparison of surfactant dosing via a dual-lumen endotracheal tube in respiratory distress syndrome. Pediatrics 1998; 101(4):1-5.
  29. Anzueto, A, Baughman, RP, Guntupalli, KK, et al: Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. The New England Journal of Medicine 1996; 334(22)1417-1421.
  30. Cosmi, E, La Torre, R, Piazze, JJ, et al: Intraamniotic surfactant for prevention of neonatal respiratory distress syndrome (IRDS). European Journal of Obstetrics & Gynecology and Reproductive Biology 1997; 71:1-39.
  31. Lisawa, J, Pietrasik, D, Zwolinski, J, et al: Intraamniotic surfactant supply as RDS prevention. Med Wieku Rozwoj 2003; 7(Suppl1):255-260.
  32. Kattwinkel, J, Robinson, M, Bloom, BT, et al: Technique for intrapartum administration of surfactant without requirement for an endotracheal tube. Journal of Perinatology 2004; 24:360-365.
  33. Cummings, JJ, Holm, BA, Hudak, ML, et al: A controlled clinical comparison of four different surfactant preparations in surfactant deficient preterm lambs. Am Rev Respir Dis 1992; 145:999-1004.
  34. Ikegami, M, Kallapur, S, Michna, J, et al: Changes in exogenous surfactant-treated preterm ventilated lambs. Am Rev Respir Dis 1993; 145: 1005-1008.
  35. Schurch, S: Surface tension properties of surfactant. Clinics in Perinatology 1993; 20:669-682.
  36. Seeger, W, Grube, C, Gunther, A, et al: Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. Eur Respir J 1993; 6:971-977.
  37. Fuj iwara, R, Maeta, H, Chida, S, et al: Artificial surfactant in hyaline membrane disease. Lancet 1980; 1 :55-59.
  38. Hall, S, Venkitaraman AR, Whitsett JA, et al: Importance of hydrophobic apoproteins as constituents of clinical exogenous surfactants. Am Rev Respir Dis 1992; 145 :24-30.
  39. Halliday, J: Natural vs synthetic surfactants in neonatal respiratory distress syndrome. Drugs 1996; 51:226-237.
  40. Bloom, B: Comparison of Infasurf (Calf Lung Surfactant Extract) to Survanta (Beractant) in the Treatment and Prevention of Respiratory Distress Syndrome. Pediatrics 1997; 100:31-38.
  41. Speer, C, Gefeller, 0, Groneck, P, et al: Randomized clinical trial of surfactant therapy for neonatal respiratory distress syndrome: Comparison of two treatment regimens with natural surfactant preparations. Arch Dis Child 1995; 72:F8-13.
  42. Fox, GF, Sorthinathan, U: The choice of surfactant for treatment of respiratory distress syndrome in pretenn infants: A review of the evidence. Infant 2005; 1(1): 8-12.
  43. Jobe, AH: Pathophysiology of respiratory distress syndrome, in Polin, RA, Fox, WW (eds): Fetal and Neonate Physiology. Philadelphia, PA, W.B. Saunders, 1992, pp 995- 1001.
  44. Findlay, R, Tauesch, W, and Walther, F: Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics 1996: 97(1 ):48-52.
  45. Harms, K, Herting, E: Successful surfactant replacement therapy in two infants with ARDS due to chlamydial pneumonia. Respiration 1994; 61 :348-352.
  46. Pandit, PB, Dunn, MS, Kelly, EN, et al: Surfactant replacement in neonates with early chronic lung disease. Pediatrics 1995; 95 :851-854.
  47. Lotze, A, Mitchell, BR, Bulas, DI, et al: Multicenter study of surfactant (Beractant) use in the treatment oftenn infants with severe respiratory failure. The Journal of Pediatrics 1998; 132(1):40-47.
  48. Auten, RL, Notter, RH, Kendig, JW, et al: Surfactant treatment of full-tenn newborns with respiratory failure. Pediatrics 1991; 87(1):101-107.
  49. Moreno, M, Lopez-Herce, J, Alcaraz, A, et al: Exogenous surfactant therapy for acute respiratory distress in infancy. Intensive Care Med 1996; 22:87-88.
  50. Herting, E, Gefeller, 0, Land, M, et al: Surfactant treatment of neaonates with respiratory failure and group B streptococcal infection. Pediatrics 2000; 106(5):957-965.
  51. Greenough, A: Expanded use of surfactant replacement therapy. Eur J Pediatr 2000; 159:635-640.
  52. Suzuki, Y: Effect of protein, cholesterol and phosphatidylglycerol on the surface activity of the lipid-protein complex reconstituted from pig pulmonary surfactant. J Lipid Res 1982; 23:62-69.
  53. Antal, J, Divis, LT, Erzurum, SC, et al: Surfactant suppresses NF-k B activation in human monocytic cells. Am J Respir Cell Mol Bioi 1996: 14(4):374-379.
  54. Rubin, BK, Ramirez, 0, King, M: Mucus rheology and transport in neonatal respiratory distress syndrome and the effect .of surfactant therapy. Chest 1992; 101: 1080- 1085.
  55. Alabaman, V, Sood, SL, Finn, KC, et al: Physiologic response and lung distribution of lavage versus bolus Exosurf in piglets with acute lung injury. Am J Respir Crit Care Med 1996; 153:1838-1843.
  56. Cochrane, CG, Revak, SD, Merritt, TA, et al: Bronchoalveolar lavage with KL4- surfactant in models of meconium aspiration syndrome. Pediatr Res 1998; 44:705-715.
  57. Ohama, Y, Itakura, Y, Koyama, N, et al: Effect of surfactant lavage in a rabbit model of meconium aspiration syndrome. Acta Paediatr Jpn 1994; 36:236-238.
  58. Baughman, R, Sternberg, R, Jull, W: Decreased surfactant protein A in patients with bacterial pneumonia. Am Rev Respir Dis 1993: 147:653.
  59. Levine, AM, Lotze, A, Stanley, S, et al: Surfactant content in children with inflammatory lung disease. Crit Care Med 1996; 24(6): 1062-1067.
  60. Holm, BA, Keicher, L, Liu, MY, et al: Inhibition of pulmonary surfactant function by phospholipases. Chem Phys Lipids 1988; 49:49.
  61. Wilson, D, Zaritsky, A, Bauman, LA, et al: Instillation of calf lung surfactant extract (calfactant) is beneficial in pediatric acute hypoxemic respiratory failure. Crit Care Med 1999; 27(1):188-195.
  62. Wilson, DF, Jiao, JH, Bauman, LA, et al: Calf's lung surfactant extract in acute hypoxemic respiratory failure in children. Crit Care Med 1996; 24(6): 1316-1322.
  63. Tibby, S, Hatherill, M, Wright, S, et al: Exogenous surfactant supplementation in infants with respiratory syncytial virus bronchiolitis. American Journal of Respiratory & Critical Care Medicine 2000; 162(4):1251-1256.
  64. Song, G, Robertson, B, Curstedt, T, et al: Surfactant treatment in experimental escherichia coli pneumonia. Acta Anaesthesiol Scand 1996; 40: 1152.
  65. van Daal, GJ, So, KL, Gammers, D, et al: Intratracheal surfactant administration restores gas exchange in experimental adult respiratory distress syndrome associated with viral pneumonia, Anesth Analg 1991; 72:589-595.
  66. van Daal, G, Bos, lA, Eijking, EP, et al: Surfactant replacement therapy improves pulmonary mechanics in end stage influenza A pneumonia. Am Rev Respir Dis 1992; 145:859.
  67. Pandit, PB, Dunn, MS, Colucci, EA: Surfactant therapy in neonates with respiratory deterioration due to pulmonary hemorrhage. Pediatrics 1995; 95(1):32-36.
  68. Bissinger, R, Carlson, C, Hulsey, T, et al: Secondary surfactant deficiency in neonates. Journal of Perinatology 2004: 24:663-666. References
  69. Hamilton, B., Ventura, S., Martin, J. & Sutton, P. in Health E-Stats (National Center for Health Statistics, Hyattsville, MD, 2004).
  70. Bancalari, E. & Gonzalez, A. in Chronic Lung Disease in early Infancy (eds. Bland, R. & Coalson, J.) 41-64 (Marcell Dekker, New York, 2000).
  71. Merrill, J. & Ballard, R. Antenatal hormone therapy for fetal lung maturation. Clinics in Perinatology 25, 983-997 (1998).
  72. Mallory, M. & Fremman, D. Respiratory Distress syndrome mortality in the United States. Journal of Perina to logy 20, 414-420 (2000).
  73. Stevenson, D. et al. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1993 through December 1994. American Journal of Obstetrics and Gynecology 179,1632-1639 (1998).
  74. Jobe, A. & Bancalarie, E. Bronchopulmonary Dysplasia. American Journal of Respiratory Critical Care Medicine 163, 1723-1729 (2001).
  75. Merrill, J. et al. Dysfunction of Pulmonary Surfactant in Chronically Ventilated Premature Infants. Pediatric Research 56, 918-926 (2004).
  76. Moreno, M., Lopez-Herce, J., Alcaraz, A., Carrillo, A. Exogenous surfactant therapy for acute respiratory distress in infancy. Intensive Care med 22, 87--88 (1996).
  77. Lopez-Herce, J., de Lucas, N., Carrillo, A., Bustinza, A., Moral, R. Surfactant treatment for acute respiratory distress syndrome. Arch Dis Child 80, 248-252 (1999).
  78. Findlay, R., Tauesch, W. & Walther, F. Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics 97, 48-52 (1996).
  79. Lotze, A., Mitchell, B.R., Bulas, D.l., Zola, E.M., Shalwitz, R.A., Gunkel, J.H., Survanta In Term Infants Study Group. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. The Journal of Pediatrics 132,40-47 (1998).
  80. Lotze, A. et al. Improved pulmonary outcome after exogenous surfactant therapy for respiratory failure in term infants requiring extracorporeal membrane oxygenation. Journal of Pediatrics 122, 261-268 (1993).
  81. Lam, B. Surfactant lavage for the management of severe meconium aspiration syndrome. Biology of the Neonate 76,10-14 (1999).
  82. Kaneko, M., Watanabe, J. & Veno, E. Surfactant lavage and replacement in meconium aspiration syndrome with pulmonary hemorrhage. Journal of Perinatal Medicine 29, 351-356 (2001).
  83. Harms, K. & Herting, E. Successful surfactant replacement therapy in two infants with ARDS due to chlamydial pneumonia. Respiration 61, 348-352 (1994).
  84. Pandit, P., Dunn, M. & Colucci, E. Surfactant therapy in neonates with respiratory deterioration due to pulmonary hemorrhage. Pediatrics 95,32-36 (1995).
  85. Auten, R. L., Notter, R.H., Kendig, J.W., Davis. J.M., Shapiro, D.L. Surfactant treatment of full-term newborns with respiratory failure. Pediatrics 87, 101-107 (1991).
  86. Amizuka, T., Shimizu, H., Niida, Y. & Ogawa, Y. Surfactant therapy in neonates with respiratory failure due to haemorrhagic pulmonary oedema. European Journal of Pediatrics 162, 697-702 (2003).
  87. Pandit, P., O'Brien, K., Asztalos, E., Colucci, E. & Dunn, M. Outcome following pulmonary haemorrhage in very low birthweight neonates treated with surfactant. Arch Dis Child Fetal Neonatal Ed 81, 40-44 (1999).
  88. Khammash., H., Perlman, M., Wojtulewicz, J., Dunn, M. Surfactant therapy in full-term neonates with severe respiratory failure. Pediatrics 92, 135-139 (1993).
  89. Davis, J. M., Richter, S.E., Dendig, J.W., Notter, R.H. High-frequency jet ventilation and surfactant treatment of newborns with severe respiratory failure. Pediatric Pulmonology 13, 108-112 (1992).
  90. Dargaville, P., Mills, J. & SolI, R. Therapeutic lung lavage for meconium aspiration syndrome in newborn infants. Cochrane Database of Syst Rev 4 (2002).
  91. Herting, E., Moller, 0., Schiffmann, J. & Robertson, B. Surfactant improves oxygenation in infants and children with pneumonia and acute respiratory distress syndrome. Acta Paediatr 91, 11 74-1178 (2002).
  92. Wiswell, T. E. et al. A multicentered, randomized, controlled trial comparing Surfaxin (Lucinactant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics 109, 1081-1087 (2002).
  93. Herting, E., Gefeller, 0., Land, M., van Sonderen, L., Harms, K., Robertson, B., Members of the Collaborative European Multicenter Study Group. Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Pediatrics 106, 957-965 (2000).
  94. Perz-Benavides, F., Riff, E. & Franks, C. Adult respiratory distress syndrome and artificial surfactant replacement in the pediatric patient. Pediatric Emergency Care 11, 153-5 (1995).
  95. Wilson, D., Zaritsky, A., Bauman, L.A., Dockery, K., James, R.L., Conrad, D., Craft, H., Novotny, W.E., Egan, E.A., Kalton, H., Members of the Mid-Atlantic Pediatric Critical Care Network. Instillation of calf lung surfactant extract (calfactant) is beneficial in pediatric acute hypoxemic respiratory failure. Crit Care Med 27,188-195 (1999).
  96. Wilson, D. F., Jiao, J.H., Bauman, L.A., Zaritsky, A., Craft, H, Dockery, K., Conrad, D., Calton, H. Calfs lung surfactant extract in acute hypoxemic respiratory failure in children. Crit Care Med 24,1316-1322 (1996).
  97. Yapicioglu, H., Yildizdas, D., Bayram, I., Sertdemir, Y. & Yilmaz, H. The use of surfactant in children with acute respiratory distress syndrome: efficacy in terms of oxygenation, ventilation and mortality. Pulmonary Pharmacology and Therapeutics 16, 327-333 (2003).
  98. Hermon, M. et a1. Surfactant therapy in infants and children: Three years experience in a pediatric intensive care unit. Shock 17, 247-251 (2002).
  99. Tibby, S., Hatherill, M., Wright, S., Wilson, P., Postle, A., Murdoch, L. Exogenous surfactant supplementation in infants with respiratory syncytial virus bronchiolitis. American Journal of Respiratory & Critical Care Medicine 162, 1251-1256 (2000).
  100. Pandit, P. B., Dunn, M.S., Kelly, E.N. Perlman, M. Surfactant replacement in neonates with early chronic lung disease. Pediatrics 95, 851-854 (1995).
  101. Merrill, J. et a1. Booster surfactant therapy beyond the first week of life in ventilated extremely low gestation age infants. Pediatric Research 56, 918-926 (2004).
  102. Bissinger, R., Carlson,C., Hulsey, T., Eicher, D. Secondary Surfactant Deficiency in Neonates. Journal of Perina to logy 24,663-666 (2004).
  103. Katz, L. & Klein, J. Repeat surfactant therapy for postsurfactant slump. Journal of Perinatology 26, 414-422 (2006).
  104. Notter, R. H., Egan, E.A., Kwong, M.S., Holm, B.A., Shapire, D.L. Lung surfactant replacement in premature lambs with extracted lipids from bovine lung lavage: effects of dose, dispersion technique and gestational age. Pediatric Research 19, 569-577 (1985).
  105. Azarow, K. et a1. Congenital Diaphragmatic Hernia--A Tale of Two Cities: The Toronto Experience. Journal Of Pediatric Surgery 32,395-400 (1997).
  106. Sakura, Y. et a1. Pulmonary Barotrauma in Congenital Diaphragmatic Hernia: A Clinicopathological Correlation. Journal Of Pediatric Surgery 34, 1813-1817 (1999).
  107. Keshen, T. et a1. Does Extracorporeal Membrane Oxygenation benefit neonates with Congenital Diaphragmatic Hernia? Application of a predictive equation. Journal Of Pediatric Surgery 32,818-22 (1997).
  108. lice, Z., Guney, C., Eray, N., Ilikkan, B. & Celayir, S. The Role of Modified Ventilatory Index in Defining the Prognosis in Surgical and Non-surgical Pediatric Patients. Internet Journal of Pulmonary Medicine 5 (2005).
  109. Rivera, R., Butt, W. & Shann, F. Predictors of mortality in children with respiratory failure: Possible indications for ECMO. Anaesthesia International 18, 385-389 (1990).
  110. Kwong, M., Egan, E., Notter, R. & Shapiro, D. Double-blinded clinical trial of calf lung surfactant extract for the prevention of hyaline membrane disease in premature infants. Pediatrics 76, 585-92 (1985).
  111. Kendig, J. et al. Surfactant replacement therapy at birth: Final analysis of a clinical trial and comparisons with similar trials. Pediatrics 82, 756-62 (1988).
  112. Finer, N. Surfactant use for neonatal lung injury: beyond Respiratory Distress Syndrome. Paediatr Respir Rev 5, S289-S297 (2004).
  113. Lewis, J. & Veldhuizen, R. Factors influencing efficacy of exogenous surfactant in acute lung injury. Biology of the Neonate 67 (supplement 1), 48-60 (1995).
  114. Cummings, J., Holm, B., Hudak, M., Ferguson, W. & Egan, E. A controlled clinical comparison of four different surfactant preparations in surfactant-deficient preterrn lambs. Am Rev Respir Dis 145,999-1004 (1992).
  115. Gommers, D. & Lachmann, B. Surfactant therapy in adult patients. Current Opinion in Critical Care 1,57-61 (1995).
  116. Enhoming, G., Shennan, A., Possmayer, F.,et a1. Prevention of neonatal respiratory distress syndrome by tracheal administration of surfactant: A randomized clinical trial. Pediatrics 76, 145-153 (1985).
  117. Dekowski, S. A., Holtzman, R.B. Surfactant replacement therapy. Pediatric Clinics of North America 45,549-572 (1998).
  118. Merritt, T. A., Hallman, M., Spragg, R., Heldt, G.P., Gilliard, N. Exogenous surfactant treatments for neonatal respiratory distress syndrome and their potential role in the adult respiratory distress syndrome. Drugs 38, 591-611 (1989).
  119. Shapiro, D., Notter, R.,Morin, F.,et al. Double blind, randomized trial of a calf lung surfactant extract, administered at birth to very premature infants for prevention of respiratory distress syndrome. Pediatrics 76, 593-5 (1986).
  120. Suresch, G. K., SolI. R.F. Current surfactant use in premature infants. Clinics in Perinatology 28, 671-694 (2001). REFERENCES
  121. Bancalari, E. and A. Gonzalez, Clinical course and lung function abnormalities during development of neonatal chronic lung disease, in Chronic Lung Disease in early Infancy, R. Bland and J. Coalson, Editors. 2000, Marcell Dekker: New York. p. 41-64.
  122. Merrill, J. and R. Ballard, Antenatal hormone therapy for fetal lung maturation. Clinics in Perinatology, 1998. 25: p. 983-997.
  123. Mallory, M. and D. Fremman, Respiratory Distress syndrome mortality in the United States. Journal of Perina to logy, 2000.20: p. 414-420.
  124. Jobe, A. and E. Bancalarie, Bronchopulmonary Dysplasia. American Journal of Respiratory Critical Care Medicine, 2001.163: p. 1723-1729.
  125. Stevenson, D., et aI., Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1993 through December 1994. American Journal of Obstetrics and Gynecology, 1998. 179:p. 1632-1639.
  126. Hamilton, B., et ai. Preliminary births for 2004 National Center for Health Statistics. Health E-Stats 2004 [cited 2006] ; Available from: http://www .cdc.gov /nchs/products/pubs/pubd/hestats/prelim births/prelim births 04.htm.
  127. Suresch, G. and R. SolI, Current surfactant use in premature infants. Clinics in Perinatology, 2001. 28(3): p. 671-694.
  128. SolI, R., Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants (Cochrane Review). The Cochrane Library, Oxford: Update Software, 2002. 1.
  129. Yost, C., SolI, RF, Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome (Cochrane Review). The Cohrane Library. Osford: Update Software, 2002(1).
  130. Taeusch, H.W., Treatment of acute (adult) respiratory distress syndrome. The Holy Grail ofsurfactant therapy. Biology of the Neonate, 2000. 77(suppl 1): p. 2- 8.
  131. Van Daal, G., et aI., Intra-tracheal surfactant administration restores gas exchange in experimental adult respiratory distress syndrome associated with viral pneumonia. AnesthAnalg, 1991.72: p. 589-595.
  132. Bernard, G.R., Artigas, A., Brigham, K.L. et aI, The American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med, 1994. 149: p. 818- 824.
  133. Lewis, J. and A. Jobe, Surfactant and the adult respiratory distress syndrome. Am Rev Respir Dis, 1993. 147: p. 218-233.
  134. Hallman, M., et aI., Evidence of lung surfactant abnormality in respiratory failure. Journal of Clinical Investigation, 1982.70: p. 673-683.
  135. Pison, U., et aI., Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am Rev Respir Dis, 1989.140: p. 1033-1039.
  136. Gregory, T., et aI., Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J oumal of Clinical Investigation, 1991. 65: p.1976-1981.
  137. Gunther, A., et aI., Surfactant alterations in severe pneumonia acute respiratory distress syndrome and cardiogenic lung edema. American Journal of Respiratory and Critical Care Medicine, 1996. 153(1): p. 176-184.
  138. Kahn, M., et aI., Phosphatidylchoine molecular species of calf lung surfactant. American Journal of Physiology, 1995.269: p. L567-L573.
  139. Chida, S., et aI., Surfactant proteins and stable microbubbles in tracheal aspirates of infants with respiratory distress syndrome: Relation to the degree of respiratory failure and response to exogenous surfactant. European Journal of Pediatrics, 1997. 156: p. 131-38.
  140. Van Iwaarden, J. and L. Van Golde, Pulmonary surfactant and lung defense. Interactions of surfactant proteins with phagorytic cells and pathogens, in Surfactant Therapy for Lung Disease, B. Robertson and H. Taeusch, Editors. 1995, Marcel Dekker: New York. p. 75.
  141. Wright, J., Immunomodulatory functions of surfactant. Physiology Review, 1997. 77: p. 931-962.
  142. Lotze, A., et aI., Improved pulmonary outcome after exogenous surfactant therapy for respiratory failure in term infants requiring extracorporeal membrane oxygenation. Journal of Pediatrics, 1993.122: p. 261-268.
  143. Beresford, M. and N. Shaw, Bronchoalveolar lavage surfactant protein A,B and D concentrations in preterm infants ventilated for respiratory distress syndrome receiving natural and synthetic surfactants. Pediatric Research, 2003. 53: p. 663- 670.
  144. Merrill, J., et aI., Dysfunction of Pulmonary Surfactant in Chronically Ventilated Premature Infants. Pediatric Research, 2004. 56(6): p. 918-926.
  145. Young, S., et aI., Pulmonary surfactant lipid production in oxygen exposed rat lungs. Lab Invest, 1982. 46: p. 570-576.
  146. Clements, J., Functions of the alveolar lining. Am Rev Respir Dis, 1977.115: p. 67-71.
  147. Tierney, D. and R. Johnson, Altered surface tension of lung extracts and lung mechanics. Journal of Applied Physiology, 1965.20: p. 1253-1260.
  148. Avery, M. and S. Said, Surface phenomenon in lungs in health and disease. Medicine, 1966. 44: p. 503-526.
  149. Holm, B., R. Notter, and J. Finkelstein, Surface property changes from interactions with albumin with natural lung surfactant and extracted lung lipids. Chern Phys Lipids, 1985.38: p. 287-298.
  150. Holm, B., G. Enhorning, and R. Notter, A biophysical mechanism by which plasma proteins and pulmonary surfactant: Pulsating bubble studies. Chern Phys Lipids, 1988. 49: p. 49-55.
  151. Seeger, W., et aI., Alterations of alveolar surfactant function after exposure to oxidative stress and to oxygenated and native arachidonic acid in vitro. Biochem Biophys Acta, 1985.835: p. 58-67.
  152. Holm, B., et aI., Inhibition of pulmonary surfactant function by phospholipases. Journal of Applied Physiology, 1991.71: p. 317-321.
  153. Niewoehner, D., K. Rice, and A.W. Sinha, D, Injurious effects of lysophophatidylcholine on barrier properties of alveolar epithelium. Journal of Applied Physiology, 1987.63: p. 1979-1986.
  154. Kobayashi, T., et aI., Inactivation of exogenous surfactant by pulmonary edema fluid. Pediatric Research, 1991.29: p. 353-356.
  155. Holm, B., et aI., Type II pneumocyte changes during hyperoxic lung injury and recovery. Journal of Applied Physiology, 1988.65: p. 2672-2678.
  156. Hallman, M., et aI., Surfactant protein-A, phosphatidylcholine, and surfactant inhibitors in epithelial lining fluid--correlation with surface activity, severity of respiratory distress syndrome and outcome in small premature infants. Am Rev RespirDis, 1991.144: p. 1376-1384.
  157. Takasuke, A., et aI., Surfactant therapy in neonates with respiratory failure due to haemorrhagic pulmonary oedema. European Journal of Pediatrics, 2003. 162: p. 697-702.
  158. Subhedar, N., et aI., A comparison of indices of respira tory failure in ventilated preterm infants. Arch Dis Child Fetal Neonatal Ed, 2000.83: p. F97-F100.
  159. Pascual, F., et aI., Assessment ofprognosis in patients with community-acquired pneumonia who require mechanical ventilation. Chest, 2000. 117: p. 503-512.
  160. Spitzer, A., J. Greenspan, and W. Fox, Positive-Pressure Ventilation: Pressure- limited and Time-cycled Ventilation, in Assisted Ventilation of the Neonate, J. Goldsmith and E. Karotkin, Editors. 2003, Saunders: Philadelphia. p. 149-169.
  161. Kendig, J., et aI., Surfactant replacement therapy at birth: Final analysis of a clinical trial and comparisons with similar trials. Pediatrics, 1988. 82: p. 756-62.
  162. Kwong, M., et aI., Double-blinded clinical trial of calf lung surfactant extract for the prevention of hyaline membrane disease in premature infants. Pediatrics, 1985. 76:p. 585-92.
  163. Fujiwara, T., et aI., Surfactant replacement therapy with a single postventilatory dose of a reconstituted bovine surfactant in preterm neonates with respiratory distress syndrome: Final analysis of a mulitcenter, double-blind, randomized trial and comparison with similar trials. Pediatrics, 1990. 86(5): p. 753-764.
  164. Hallman, M., et a1., Exogenous human surfactantfor treatment of severe respiratory distress syndrome: A randomized prospective clinical trial. The Journal of Pediatrics, 1985. 106(6): p. 963-969.
  165. Yapicioglu, H., et a1., The use of surfactant in children with acute respiratory distress syndrome: efficacy in terms of oxygenation, ventilation and mortality. Pulmonary Pharmcology and Therapeutics, 2003. 16: p. 327-333.
  166. Rosaint, R., et ai., Inhaled nitric oxide for the adult respiratory distress syndrome. New England Journal of Medicine, 1993.328: p. 399-405.
  167. Rivera, R., W. Butt, and F. Shann, Predictors of mortality in children with respiratory failure: Possible indications for ECMO. Anaesthesia International, 1990. 18:p. 385-389.
  168. lIce, Z., et a1., The Role of Modified Ventilatory Index in Defining the Prognosis in Surgical and Non-surgical Pediatric Patients. Internet Journal of Pulmonary Medicine, 2005. 5(1).
  169. Sakura, Y., et a1., Pulmonary Barotrauma in Congenital Diaphragmatic Hernia: A Clinicopathological Correlation. Journal QfPediatric Surgery, 1999.34(12): p. 1813-1817.
  170. Azarow, K., et a1., Congenital Diagphragmatic Hernia--A Tale of Two Cities: The Toronto Experience. Journal QfPediatric Surgery, 1997.32(3): p. 395-400.
  171. Keshen, T., et ai., Does Extracorporeal Membrane Oxygenation benefit neonates with Congenital Diaphragmatic Hernia? Application of a predictive equation. Journal QfPediatric Surgery, 1997.32(6): p. 818-22.
  172. Germain, J., C. Fornoux, and D. Pinquire, Can blood gas values predict pulmonary hypoplasia in antenatally diagnosed congenital diaphragmatic hernia? Journal QfPediatric Surgery, 1996.31: p. 1634-1639.
  173. Norden, M., W. Butt, and P. McDougall, Predictors of survival for infants with congenital diaphragmatic hernia. Journal QfPediatric Surgery, 1994.29: p. 1442-1446.
  174. Numanoglu, A., C. Morrison, and H. Rode, Prediction of outcome in congenital diaphragmatic hernia. Pediatric Surg Int, 1998. 13: p. 564-568.
  175. lice, Z., et aI., The role of modified ventilation index in defining the prognosis in congenital diaphragmatic hernia. Ulusal Cocuk Cerrahisi Kongresi Antalya (Turkish with English Abstract), 2001.19.
  176. Wilson, D., et aI., Calfs lung surfactant extract in acute hypoxemic respiratory failure in children. Critical Care Medicine, 1996.24(6): p. 1316-1322.
  177. Tibby, S., et ai., Exogenous surfactant supplementation in infants with respiratory syncytial virus bronchiolitis. American Journal of Respiratory and Critical Care Medicine, 2000.162: p. 1251-1256.
  178. Notter, R., et aI., Lung Surfactant replacement in premature lambs with extract lipids from bovine lung lavage: Effects of dose, dispersion technique, and gestational age. Pediatric Research, 1985. 19: p. 569-77.
  179. Suzuki, K., Respiratory characteristics ofinfants with pulmonary hypoplasia syndrome following premature rupture of membranes: a preliminary study for establishing clinical diagnostic criteria. Early Human Development, 2004. 79: p. 31-40.
  180. Notter, R. and B. Holm, Basic science research on clinical exogenous surfactants: composition, activity, viscosity and utility in lung injury. Neonatal Intensive Care, 2004. 17(2): p. 37.
  181. Pandit, P., et aI., Surfactant replacement in neonates with early chronic lung disease. Pediatrics, 1995. 95: p. 851-854.
  182. Lachmann, B. and E. Danzmann, Adult respirtory distress syndrome, in Pulmonary Surfactant, B. Robertson, L. Van Golde, and J. Batenburg, Editors. 1984, Elsevier: Amsterdam, Netherlands. p. 505.
  183. Holm, B. and R. Notter, Effects of hemoglobin and cell membrane lipids on pulmonary surfactant activity. Journal of Applied Physiology, 1987.63(1): p. 1434-1442.
  184. Nishina, K., et aI., Effects of exogenous surfactant on acute lung injury induced by intratracheal instillation of infant formula or human breast milk in rabbits. Anesthesiology, 1999.91: p. 240-252.
  185. Richman, P., et aI., The adult respiratory distress syndrome: First trials with surfactant replacement. European Respiratory Journal, 1989.2 (Supplement 3): p.109S-111S.
  186. Walmrath, D., et aI., Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. American Journal of Respiratory Critical Care Medicine, 1996. 154: p. 57-62.
  187. Gregory, T., et aI., Bovine surfactant therapy for patients with acute respiratory distress syndrome. American Journal of Respiratory Critical Care Medicine, 1997. 155: p. 1309-15.
  188. Spragg, R., et aI., Acute effects of a single dose ofporcine surfactant on patients with the adult respiratory distress syndrome. Chest, 1994. 105: p. 195-202.
  189. Lachmann, B., Animal models and clinical pilot studies of surfactant replacement in adult respiratory distress syndrome. European Respiratory Journal, 1989.2 (Supplement 3): p. 98-103.
  190. Reines, H., et aI., Effects of two concentrations of nebulized surfactant (Exosurj) in sepsis-induced adult respiratory distress syndrome (ARDS). Critical Care Medicine, 1992. 20: p. S61. Abstract.
  191. Adhikari, N., K. Burns, and M. Meade (2004) Pharmacologic therapies/or adults with acute lung injury and acute respiratory distress syndrome. Cochrane Database of Systematic Reviews Volume, DOl: DOl: 10.1002/14651858.CD004477.pub2.
  192. Perz-Benavides, F., E. Riff, and C. Franks, Adult respiratory distress syndrome and artificial surfactant replacement in the pediatric patient. Pediatric Emergency Care, 1995. 11: p. 153-5.
  193. Moreno, M., Lopez-Herce, J., Alcaraz, A., Carrillo, A., Exogenous surfactant therapy for acute respiratory distress in infancy. Intensive Care med, 1996.22: p. 87--88.
  194. Lopez-Herce, J., et aI., Surfactant treatment for acute respiratory distress syndrome. Arch Dis Child, 1999.80: p. 248-252.
  195. DeBruin, W., et aI., Acute hypoxemic respiratory failure in infants and children: Clinical and pathologic characteristics. Crit Care Med, 1992.20(9): p. 1223- 1234.
  196. Timmons, 0., P. Havens, and J. Fackler, Predicting death in pediatric patients with acute respiratory failure. Chest, 1995. 108: p. 789-797.
  197. Wilson, D., et aI., Instillation of calf lung surfactant extract (calfactant) is beneficial in pediatric acute hypoxemic respiratory failure. Critical Care Medicine, 1999. 27: p. 188-95.
  198. Hermon, M., et aI., Surfactant therapy in infants and children: Three years experience in a pediatric intensive care unit. Shock, 2002. 17(4): p. 247-251.
  199. Timmons, 0., J. Dean, and D. Vernon, Mortality rates and prognostic variables in children with adult respiratory distress syndrome. Journal of Pediatrics, 1991. 119: p. 896-899.
  200. Lotze, A., et aI., Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta In Term Infants Study Group. The Journa/ of Pediatrics , 1998.132(1): p. 40-47.
  201. Findlay, R., H. Taeusch, and F. Walther, Surfactant replacment therapy for meconium aspiration syndrome. Pediatrics, 1996.97(48-52).
  202. Lam, B., Surfactant lavage for the management of severe meconium aspiration syndrome. Biology of the Neonate, 1999.76: p. 10-14.
  203. Kaneko, M., J. Watanabe, and E. Veno, Surfactant lavage and replacement in meconium aspiration syndrome with pulmonary hemorrhage. Journal of Perinatal Medicine, 2001. 29: p. 351-356.
  204. Harms, K. and E. Herting, Successful surfactant replacement therapy in two infants with ARDS due to chlamydial pneumonia. Respiration, 1994. 61: p. 348- 352.
  205. Kerr, M. and J. Paton, Surfactant protein levels in severe respiratory syncytial virus infection. American Journal of Respiratory Critical Care Medicine, 1999. 159: p. 1115-1118.
  206. Pandit, P., M. Dunn, and E. Colucci, Surfactant therapy in neonates with respiratory deterioration due to pulmonary hemorrhage. Pediatrics, 1995. 95( 1): p.32-36.
  207. Amizuka, T., et aI., Surfactant therapy in neonates with respiratory failure due to haemorrhagic pulmonary oedema. European Journal of Pediatrics, 2003.162: p. 697-702.
  208. Pandit, P., et aI., Outcomefollowingpulmonary haemorrhage in very low birthweight neonates treated with surfactant. Arch Dis Child Fetal Neonatal Ed, 1999. 81: p. 40-44.
  209. Auten, R., et aI., Surfactant treatment offull-term newborns with respiratory failure. Pediatrics, 1991.87(1): p. 101-107.
  210. Khammash, H., et aI., Surfactant therapy infull-term neonates with severe respiratory failure. Pediatrics, 1993.92(1): p. 135-139.
  211. Herting, E., et al., Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Members of the Collaborative European Multicenter Study Group. Pediatrics, 2000. 106(5): p. 957-965.
  212. Herting, E., et ai., Surfactant improves oxygenation in infants and children with pneumonia and acute respiratory distress syndrome. Acta Paediatr, 2002. 91: p. 1174-1178.
  213. Jobe, A.H., Ikegami, M., Biology of surfactant. Clinics in Perinatology, 2001. 28(3): p. 655-669.
  214. Odita, J., The significance of recurrent lung opacities in neonates on surfactant treatmentfor respiratory distress syndrome. Pediatric Radiology, 2001. 31(2): p. 87-91.
  215. Sobel, D. and A. CaroB, Post surfactant slump: early prediction of chronic neonatal lung disease. Journal of Perina to logy, 1994. 14: p. 264-274.
  216. Davis, J., et aI., High-frequency jet ventilation and surfactant treatment of newborns with severe respiratory failure. Pediatric Pulmonology, 1992. 13: p. 108-112.
  217. Merrill, J., et aI., Booster surfactant therapy beyond the first week of life in ventilated extremely low gestation age infants. Pediatric Research, 2004. 56: p. 918-926.
  218. Katz, L. and J. Klein, Repeat surfactant therapy for postsurfactant slump. Journal of Perina to logy, 2006.26: p. 414-422.
  219. Thibeault, D., et aI., Lung elastic tissue maturation and perturbations during the evolution of chronic lung disease. Pediatrics, 2000. 106(6): p. 1452-1459.
  220. Bissinger, R., et aI., Secondary surfactant deficiency in neonates. Journal of Perinatology, 2004. 24(10): p. 663-666.
  221. Jobe, A. and M. Ikegami, Surfactant and Acute Lung Injury. Proceedings of the Association of American Physicians, 1998. 110(6): p. 489-495.
  222. Ware, L. and M. Matthay, The acute respiratory distress syndrome. The New England Journal of Medicine, 2000. 342(18): p. 1334-1349.
  223. Jobe, A.H., Pathophysiology of respiratory distress syndrome, in Fetal and Neonatal Physiology, R.A. Polin, Fox, W.W., Editor. 1992, W.B.Saunders Company: Philadelphia. p. 995-1001.
  224. Clark, R., et ai., Lung Injury in neonates: causes, strategies for prevention, and long-term consequences. Journal of Pediatrics, 2001.139: p. 478-486.
  225. Lopez-Herce, J., de Lucas, N., Carrillo, A., Bustinza, A., Moral, R., Surfactant treatmentfor acute respiratory distress syndrome. Arch Dis Child, 1999.80: p. 248-252.
  226. Findlay, R., W. Tauesch, and F. Walther, Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics, 1996.97(1): p. 48-52.
  227. Lotze, A., Mitchell, B.R., Bulas, D.l., Zola, E.M., Shalwitz, R.A., Gunkel, J.H., Survanta In Term Infants Study Group, Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. The Journal of Pediatrics, 1998. 132(1): p. 40-47.
  228. Auten, R.L., Notter, R.H., Kendig, J.W., Davis. J.M., Shapiro, D.L, Surfactant treatment of full-term newborns with respiratory failure. Pediatrics, 1991. 87( 1): p. 101-107.
  229. Khammash, H., Perlman, M., Wojtulewicz, J., Dunn, M., Surfactant therapy in full-term neonates with severe respiratory failure. Pediatrics, 1993.92(1): p. 135- 139.
  230. Davis, J.M., Richter, S.E., Dendig, J.W., Notter, R.H., High-frequency jet ventilation and surfactant treatment of newborns with severe respiratory fallure. Pediatric Pulmonology, 1992. 13: p. 108-112.
  231. Dargaville, P., J. Mills, and R. Soll, Therapeutic lung lavage for meconium aspiration syndrome in newborn infants. Cochrane Database of Syst Rev, 2002. 4.
  232. Wiswell, T.E., et aI., A multicentered, randomized, controlled trial comparing Surfaxin (Lucinactant) lavage with standard carefor treatment ofmeconium aspiration syndrome. Pediatrics, 2002. 109: p. 1081-1087.
  233. Herting, E., Gefeller, 0., Land, M., van Sonderen, L., Harms, K., Robertson, B., Members of the Collaborative European Multicenter Study Group, Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Pediatrics, 2000. 106(5): p. 957-965.
  234. Wilson, D., Zaritsky, A., Bauman, L.A., Dockery, K., James, R.L., Conrad, D., Craft, H., Novotny, W.E., Egan, E.A., Kalton, H., Members of the Mid-Atlantic Pediatric Critical Care Network, Instillation of calf lung surfactant extract (calfactant) is beneficial in pediatric acute hypoxemic respiratory failure. Crit Care Med, 1999.27(1): p. 188-195.
  235. Wilson, D.F., Jiao, J.H., Bauman, L.A., Zaritsky, A., Craft, H, Dockery, K., Conrad, D., Calton, H., Calfs lung surfactant extract in acute hypoxemic respiratory failure in children. Crit Care Med, 1996.24(6): p. 1316-1322.
  236. Yapicioglu, H., et aI., The use of surfactant in children with acute respiratory distress syndrome: efficacy in terms of oxygenation, ventilation and mortality. Pulmonary Pharmacology and Therapeutics, 2003. 16: p. 327-333.
  237. Tibby, S., Hatherill, M., Wright, S., Wilson, P., Postle, A., Murdoch, L., Exogenous surfactant supplementation in infants with respiratory syncytial virus bronchiolitis. American Journal of Respiratory & Critical Care Medicine, 2000. 162(4): p. 1251-1256.
  238. Pandit, P.B., Dunn, M.S., Kelly, E.N. Perlman, M., Surfactant replacement in neonates with early chronic lung disease. Pediatrics, 1995.95: p. 851-854.
  239. Bissinger, R., Carlson,C., Hulsey, T., Eicher, D., Secondary Surfactant Deficiency in Neonates. Journal of Perina to logy, 2004.24: p. 663-666.
  240. Notter, R.H., Egan, E.A., Kwong, M.S., Holm, B.A., Shapire, D.L., Lung surfactant replacement in premature lambs with extracted lipids from bovine lung lavage: effects of dose, dispersion technique and gestational age. Pediatric Research, 1985. 19: p. 569-577.
  241. Azarow, K., et aI., Congenital Diaphragmatic Hernia--A Tale of Two Cities: The Toronto Experience. Journal QfPediatric Surgery, 1997.32(3): p. 395-400.
  242. Finer, N., Surfactant usefor neonatal lung injury: beyond Respiratory Distress Syndrome. Paediatr Respir Rev, 2004. 5: p. S289-S297.
  243. Lewis, J. and R. Veldhuizen, Factors influencing efficacy ofexogenous surfactant in acute lung injury. Biology of the Neonate, 1995.67 (supplement 1): p. 48-60.
  244. Cummings, l., et aI., A controlled clinical comparison offour different surfactant preparations in surfactant-deficient preterm lambs. Am Rev Respir Dis, 1992. 145: p. 999-1004.
  245. Gommers, D. and B. Lachmann, Surfactant therapy in adult patients. Current Opinion in Critical Care, 1995.1: p. 57-61.
  246. Enhoming, G., et aI., Prevention of neonatal respiratory distress syndrome by tracheal administration of surfactant: A randomized clinical trial. Pediatrics, 1985. 76:p. 145-153.
  247. Dekowski, S.A., Holtzman, R.B., Surfactant replacement therapy. Pediatric Clinics of North America, 1998.45(3): p. 549-572.
  248. Merritt, T.A., Hallman, M., Spragg, R., Heldt, G.P., Gilliard, N., Exogenous surfactant treatments for neonatal respiratory distress syndrome and their potential role in the adult respiratory distress syndrome. Drugs, 1989. 38(4): p. 591-611.
  249. Shapiro, D., et aI., Double blind, randomized trial of a calf lung surfactant extract, administered at birth to very premature infants for prevention of respiratory distress syndrome. Pediatrics, 1986. 76: p. 593-5.
  250. Suresch, G.K., SolI. R.F., Current surfactant use in premature infants. Clinics in Perinatology, 2001. 28(3): p. 671-694.
  251. lobe, A.H. and M. Ikegami, Update on Mechanical Ventilation and Exogenous Surfactant. Clinics in Perinatology, 2001.28(3).

Related papers

Secondary surfactant administration in neonates with respiratory decompensation
Cheryl Carlson

Journal of Perinatology, 2008

Objective: To evaluate blood gases and ventilatory parameters before and after two doses of surfactant in premature infants with respiratory decompensation after recovery from primary respiratory distress syndrome (RDS). Study Design: This prospective pilot study enrolled infant's X500 g birth weight, from 7 days to 3 months of age, with a secondary respiratory decompensation lasting at least 4 h prior to study entry. Infants received two doses of surfactant, 12 h apart. Result: A total of 20 neonates qualified for secondary surfactant administration. PCO 2 (P<0.001); pH (P<0.001); mean airway pressure (P<0.05); FiO 2 (P<0.05); modified ventilatory indices (P<0.004) and respiratory severity scores (P<0.001) improved significantly at both 12 and 24 h after surfactant administration. Conclusion: Secondary surfactant administration may be effective in reducing short-term ventilatory requirements in neonates who have a respiratory decompensation after recovery from initial RDS. Randomized controlled trials are needed to confirm these preliminary findings.

View PDFchevron_right
Surfactant replacement therapy in premature babies with respiratory distress syndrome: factors affecting the response to surfactant and comparison of outcome from 1982-86 and 1987-91
Yutaka Fujii

Acta paediatrica Japonica; Overseas edition, 1992

The impact of surfactant therapy on chronic lung disease remains uncertain. During the past decade (1982-91), over 300 babies with respiratory distress syndrome (RDS) weighing 501-2,500 g at birth were consecutively treated with surfactant-TA at our neonatal intensive care unit. Data on 95 RDS babies treated in the first 5 year period (Period 1, 1982-86) were compared with those on 158 RDS babies treated in the second 5 year period (Period 2, 1987-91). Overall respiratory improvement was better in Period 2 than in Period 1. In Period 2, surfactant therapy converted 98% of the babies with moderate/severe RDS to those with &#39;near normal&#39; lung by 72 hr post-treatment. In Period 2, 95% of the surfactant-treated babies weighing 501-1,750 g at birth survived, 97% of which required no supplemental oxygen at 40 weeks corrected gestational age. Increased survival rate in the surfactant-treated babies during the past decade has not been followed by a parallel increase in chronic lung d...

View PDFchevron_right
Is there a necessity for multiple doses of surfactant for respiratory distress syndrome of premature infants?
Charalampos Dokos

2012

Both prophylactic and early surfactant (SF) replacement therapy reduce pulmonary complications and mortality in ventilated infants with respiratory distress syndrome (RDS). The effectiveness of one or more doses and the impact on morbidity and mortality of premature neonates with RDS need to be further clarified. The objective of this study was to investigate the necessity of repeated surfactant replacement therapy in premature infants≤ 32 weeks of gestational age and the possibility of an underlying pathology.

View PDFchevron_right
Early versus Delayed Selective Surfactant Treatment for Neonatal Respiratory Distress Syndrome
Wissal Ben Jmaa

Neonatology, 2013

not specifically for surfactant dosage) within the first 2 h of life versus delayed selective surfactant administration to infants with established RDS were considered for review. Data Collection and Analysis: Data regarding clinical outcomes were excerpted from the reports of the clinical trials by the review authors. Subgroup analyses were performed based on type of surfactant preparation, gestational age, and exposure to prenatal steroids. Data analysis was performed in accordance with the standards of the Cochrane Neonatal Review Group. Main Results: Six randomized controlled trials met selection criteria. Two of the trials utilized synthetic surfactant (Exosurf Neonatal) and four utilized animal-derived surfactant preparations. The meta-analyses demonstrate significant reductions in the risk of neonatal mortality (typical risk ratio (RR) 0.84; 95% confidence interval (CI) 0.74-0.95; typical risk difference (RD)-0.04; 95% CI-0.06 to-0.01; 6 studies; 3,577 infants), chronic lung disease (typical RR 0.69; 95% CI 0.55-0.86; typical RD-0.04; 95% CI-0.06 to-0.01; 3 studies; 3,041 infants), and chronic lung disease or death at 36 weeks (typical RR 0.83; 95% CI 0.75-0.91; typical RD-0.06; 95% CI-0.09 to-0.03; 3 studies; 3,050 infants) associated with early treatment of intubated infants with RDS. Intubated infants randomized to early selective surfactant administration also demonstrated a decreased risk of acute lung injury including a decreased risk of pneumothorax (typical RR 0.69; 95% CI 0.59-0.82; typical RD-0.05; 95% CI-0.08 to-0.03; 5 studies; 3,545 infants), pulmonary interstitial emphysema (typical RR 0.60; 95% CI 0.41-0.89; typical RD-0.06; 95% CI-0.10 to-0.02; 3 studies; 780 infants), and overall air leak syndromes (typical RR 0.61; 95% CI 0.48-0.78; typical RD-0.18; 95% CI-0.26 to-0.09; 2 studies; 463 infants). A trend

View PDFchevron_right
Outcome of Very Premature Newborn Receiving an Early Second Dose of Surfactant for Persistent Respiratory Distress Syndrome
Muhammad Fadhullah

2021

Background: Infants presenting respiratory distress syndrome (RDS) not responding to surfactant often receive a second instillation. Few studies evaluated the consequences of this second administration. This study aimed at determining the outcome of infants presenting persistent RDS and receiving an early second dose of surfactant. Methods: Infants below 32 weeks&#39; gestation who received a second dose of 100mg/kg of surfactant within the first 72 h of life, were retrospectively involved in this 42 months&#39; study. They were matched to two controls receiving a single dose of 200mg/Kg based upon gender and gestational age. Results: 52/156 infants receiving two doses (Group 2-doses) were significantly more often SGA [22 (42%) vs. 21 (20%) p = 0.04] and outborn [29 (56%) vs. 13 (12%) p = 0.001]. They had received antenatal corticos teroid therapy less often [26 (50%) vs. 89 (86%) p = 0.001] and presented more severe RDS based upon FiO2 level, oxygenation index and radiography. Grou...

View PDFchevron_right
580 California St., Suite 400
San Francisco, CA, 94104
© 2025 Academia. All rights reserved